
Opinion|Videos|January 1, 2025
The Impact of Mutational Burden on Responses With Frontline Luspatercept in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss how mutational burden impacts the response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), highlighting its role in predicting treatment outcomes and the duration of transfusion independence.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















